Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Could Release GMP Data To Prod Manufacturing Improvements

This article was originally published in The Pink Sheet Daily

Executive Summary

Batch failure and other measures commonly tracked by manufacturers could be aggregated into an industry-wide index that FDA would use to help make risk-based inspection decisions.

You may also be interested in...



US FDA Quality Metrics Initiative Continues Moving Forward … Quietly

Despite few public announcements and industry concerns, FDA's Office of Pharmaceutical Quality director says program is not dead.

FDA Mutual Reliance with EU on Inspections Is Slow Going

FDA still does over 40% of its inspections in Europe even as it acknowledges it must spend the money elsewhere.

FDA Mutual Reliance With EU On Inspections Is Slow Going

FDA still does over 40% of its inspections in Europe even as it acknowledges it must spend the money elsewhere.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS075960

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel